Stock Track | CareDx Plunges 5.07% After-Hours Despite Strong Q1 Results as Acquisition of Naveris Raises Investor Concerns

Stock Track04-29

CareDx Inc. (CDNA) experienced a significant after-hours plunge of 5.07% following the release of its first-quarter 2026 financial results and the announcement of a major acquisition.

The transplant diagnostics firm reported robust Q1 performance, with revenue rising 39% year-over-year to $118 million, beating analyst estimates of $104.03 million. The company also posted adjusted earnings per share of $0.34, significantly above the consensus estimate of $0.13. Furthermore, CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million and announced a $100 million share buyback program.

Despite these positive indicators, investor sentiment turned negative following the simultaneous announcement that CareDx has entered into an agreement to acquire Naveris, a leader in viral-mediated cancer MRD surveillance testing. The deal includes $160 million in upfront cash and potential milestone payments of up to $100 million. Market participants in the post-market session appear to be weighing the costs and integration risks of the acquisition against the strong quarterly fundamentals, leading to the sharp sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100006532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100006532","market":"hk","top_or_hot":-1,"title":"Stock Track | CareDx Plunges 5.07% After-Hours Despite Strong Q1 Results as Acquisition of Naveris Raises Investor Concerns","media":"Stock Track","content":"<p>CareDx Inc. (CDNA) experienced a significant after-hours plunge of 5.07% following the release of its first-quarter 2026 financial results and the announcement of a major acquisition.</p><p>The transplant diagnostics firm reported robust Q1 performance, with revenue rising 39% year-over-year to $118 million, beating analyst estimates of $104.03 million. The company also posted adjusted earnings per share of $0.34, significantly above the consensus estimate of $0.13. Furthermore, CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million and announced a $100 million share buyback program.</p><p>Despite these positive indicators, investor sentiment turned negative following the simultaneous announcement that CareDx has entered into an agreement to acquire Naveris, a leader in viral-mediated cancer MRD surveillance testing. The deal includes $160 million in upfront cash and potential milestone payments of up to $100 million. Market participants in the post-market session appear to be weighing the costs and integration risks of the acquisition against the strong quarterly fundamentals, leading to the sharp sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CareDx Plunges 5.07% After-Hours Despite Strong Q1 Results as Acquisition of Naveris Raises Investor Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CareDx Plunges 5.07% After-Hours Despite Strong Q1 Results as Acquisition of Naveris Raises Investor Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CareDx Inc. (CDNA) experienced a significant after-hours plunge of 5.07% following the release of its first-quarter 2026 financial results and the announcement of a major acquisition.</p><p>The transplant diagnostics firm reported robust Q1 performance, with revenue rising 39% year-over-year to $118 million, beating analyst estimates of $104.03 million. The company also posted adjusted earnings per share of $0.34, significantly above the consensus estimate of $0.13. Furthermore, CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million and announced a $100 million share buyback program.</p><p>Despite these positive indicators, investor sentiment turned negative following the simultaneous announcement that CareDx has entered into an agreement to acquire Naveris, a leader in viral-mediated cancer MRD surveillance testing. The deal includes $160 million in upfront cash and potential milestone payments of up to $100 million. Market participants in the post-market session appear to be weighing the costs and integration risks of the acquisition against the strong quarterly fundamentals, leading to the sharp sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"","article_id":"1100006532","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100006532","pubTimestamp":1777408376,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CareDx Inc. (CDNA) experienced a significant after-hours plunge of 5.07% following the release of its first-quarter 2026 financial results and the announcement of a major acquisition.The transplant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx"},"translate_title":"个股追踪|CareDx盘后暴跌5.07%，尽管Q1业绩强劲，因收购Naveris引发投资者担忧","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1},"content_text":"CareDx Inc. (CDNA) experienced a significant after-hours plunge of 5.07% following the release of its first-quarter 2026 financial results and the announcement of a major acquisition.The transplant diagnostics firm reported robust Q1 performance, with revenue rising 39% year-over-year to $118 million, beating analyst estimates of $104.03 million. The company also posted adjusted earnings per share of $0.34, significantly above the consensus estimate of $0.13. Furthermore, CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million and announced a $100 million share buyback program.Despite these positive indicators, investor sentiment turned negative following the simultaneous announcement that CareDx has entered into an agreement to acquire Naveris, a leader in viral-mediated cancer MRD surveillance testing. The deal includes $160 million in upfront cash and potential milestone payments of up to $100 million. Market participants in the post-market session appear to be weighing the costs and integration risks of the acquisition against the strong quarterly fundamentals, leading to the sharp sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100006532","isCrawlerRequest":true}